At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 9 enrolled
Drug / intervention
Alemtuzumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)
University of Texas Southwestern Medical Center·interventional·Posted May 1, 2017·Updated Feb 15, 2022
In Brief
A Phase 4 clinical trial evaluating Alemtuzumab for Multiple Sclerosis (MS). Completed, enrolled 9 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple sclerosis (RRMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis (MS)
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2018
Primary CompletionNov 2020
TodayJul 2026
First PostedMay 1, 2017
Enrollment StartMay 1, 2018
Primary CompletionNov 4, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.2 years ago
Interventions
Alemtuzumabdrug
Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.